Stock Ratings / Health Care / ARDX / options

COLL (59) HELP (54) ANNX (30) AVBP (29) ⌘ Pro Terminal →

Ardelyx Inc. (ARDX) Options Positioning, Max Pain & Unusual Sweeps

Q: Where is ARDX trading relative to its 50-day, 200-day, and 52-week technical levels?

ARDX last traded at $3.03 (-2.26% on volume of 3,625,905 shares), positioning the stock -11.14% below its 50-day simple moving average ($3.41) and -43.05% below its 200-day simple moving average ($5.32). Across its 52-week range of $2.95 to $8.40, ARDX sits at the 1.5% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.6% ($2.77 to $3.29).

Q: What is ARDX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ARDX.

$3.03 -2.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.01

Ardelyx Inc. (ARDX) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $772.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ARDX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ARDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Ardelyx Inc. (NASDAQ: ARDX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $3.03 (-2.26% 1D, market cap $772.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ARDX ranks #953 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ARDX compare to COLL and HELP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARDX carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 90.3%, and ROIC of -32.7%. By comparison, COLL (Collegium Pharmaceutical Inc.) holds a C- grade (59/100 RQD, P/E 12.4x, ROIC 85.0%, cap $782.3M) and HELP (Helus Pharma Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $782.5M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ARDX?

▼

Per ARDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001437402), Ardelyx Inc. generated $407.3M in revenue (+22.1% YoY), -$62.0M in net income, and -$44.0M in free cash flow against $501.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.01 (-0.60%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ARDX)Realized 20D OHLCV Swing Band: ±8.6%

Deterministic 5-Pillar Attribution (24/100 Composite)

🔍 WHY ARDX SCORES 24/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (33% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 90.3% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.23-4.3% Next Q

Q2 (-2Q)

Grade E$3.09-2.9% Next Q

Q3 (-1Q)

Grade E$3.00+1% Next Q

Current

Grade E$3.03-10.9% Hist 90D α

Trajectory: E (32) → E (24)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ARDX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ARDX currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.41) and Max Pain ($3.18) forces dealer call-delta covering toward $8.82.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ARDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ARDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 24%NO 76%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±8.6%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ARDX)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ARDX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ARDX)

✓Walkthrough of ARDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ARDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -58.49%🛡️ HOLDING TREND SUPPORT

2026-11-02O $3.10H $3.10L $3.03C $3.03VOL 2.55M

SUP: $2.67SMA50: $3.41SMA200: $5.32

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ARDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ARDX Butterfly Map → + Track ARDX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +22.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ARDX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ARDX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ARDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ARDX)

Health Care Rank #953 of 1016 ⚔️ COLL vs ARDX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ARDX vs. COLL, HELP, ANNX, AVBP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Ardelyx Inc. (ARDX) ranks #953 by composite RQD confidence (24/100, grade E) and #391 by equity capitalization ($772.5M). Within this direct 5-issuer industry benchmark cohort, COLL leads on earnings valuation at 12.4x trailing P/E, while COLL leads on capital efficiency and profitability with 85.0% ROIC and 59.3% gross margin. COLL currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with ARDX at 24/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ARDX ACTIVE Ardelyx Inc.	E	24/100	—	90.3%	-32.7%	-2.26%	$772.5M	Benchmark Subject
COLL Collegium Pharmaceutical Inc.	C-	59/100	12.4x	59.3%	85.0%	-0.96%	$782.3M	/coll-vs-ardx →
HELP Helus Pharma Inc.	D+	54/100	—	—	—	-1.07%	$782.5M	/help-vs-ardx →
ANNX Annexon Inc.	E	30/100	—	—	-35.0%	+1.00%	$760.2M	/annx-vs-ardx →
AVBP ArriVent BioPharma Inc.	E	29/100	—	—	-35.0%	-6.77%	$786.5M	/avbp-vs-ardx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001437402

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ardelyx Inc. (ARDX) reported GAAP revenue of $407.3M (+22.1% vs. FY2024 revenue of $333.6M , and +227.3% cumulative change since FY2023) , GAAP net income of -$62.0M, operating cash flow of -$42.5M, and free cash flow of -$44.0M (+4.0% YoY). On the balance sheet, ARDX closed FY2025 with $501.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$407.3M	-$62.0M	-$42.5M	-$44.0M	$501.6M	—
FY2024 (FY)	2024-12-31	$333.6M	-$39.0M	-$44.8M	-$45.8M	$435.8M	—
FY2023 (FY)	2023-12-31	$124.5M	-$66.0M	-$89.7M	-$89.7M	—	—

3. ARDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ARDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ARDX compare to COLL and HELP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ARDX?

Where is ARDX trading relative to its 50-day, 200-day, and 52-week technical levels?

ARDX last traded at $3.03 (-2.26% on volume of 3,625,905 shares), positioning the stock -11.14% below its 50-day simple moving average ($3.41) and -43.05% below its 200-day simple moving average ($5.32). Across its 52-week range of $2.95 to $8.40, ARDX sits at the 1.5% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.6% ($2.77 to $3.29).

ARDX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ARDX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ARDX.

Direct Sub-Reports: ARDX RQD Cockpit ARDX 12M Forecast ARDX Earnings & Move ARDX Dividends & DRIP ARDX Insiders & 13F ARDX Whale Options ARDX Profit Sankey ARDX News & Why

ROARABLE RATING BRIEF • RQD 24/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ARDX — Ardelyx Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:33:03Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ARDX scores 24 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 5/20 (ROIC of -32.7% and FCF yield of -5.69%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 5/20 (Beta of 1.0 and sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z of 0.2, Piotroski F of 4/9, Debt/Equity of 0.5). For a prospective investor, the weakest pillars are the cash-generation and ownership-flow measures, both of which indicate the business is not currently returning capital on invested funds and that little visible conviction is present among tracked holders. The balance-sheet pillar, while the strongest of the five, still reflects a distressed-range Altman Z reading. The main upside case would require a reversal in cash generation, which the current source data does not show. Valuation tradeoffs are difficult to assess because earnings-based multiples are not available in the source data, so the stock's price of 3.1 cannot be measured against earnings. Any evaluation should treat the rating as a risk-screening signal rather than a directional forecast.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$407.3M	$-41.0M	$-62.0M	N/A	$-44.0M	$68.0M	N/A
FY 2024	$333.6M	$-27.9M	$-39.0M	N/A	$-45.8M	$64.9M	N/A
FY 2023	$124.5M	$-63.3M	$-66.0M	N/A	$-89.7M	N/A	N/A

Per the SEC financials, revenue rose from $124.5M in FY 2023 to $407.3M in FY 2025, while operating income and net income remained negative in every reported period. Per the market data, operating margin is -10.1%, net margin is -15.2%, and ROIC is -32.7%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 4/9, with Debt/Equity of 0.5; these figures point to a weak balance-sheet posture despite reported cash of $68.0M for FY 2025.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the flagged items are largely law-firm and class-action notices alongside general analyst commentary. The most significant item is a RISK WATCH-tagged notice referencing a securities fraud lawsuit with an investor opportunity window, rated RED. Several items concern a securities class action notice tied to ARDX stockholders, and multiple outlets carry general market commentary, all tagged YELLOW. A Seeking Alpha piece titled to revisit the thesis questions the lack of progress over two years. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded for ARDX.

Open Questions

What are the company's product lines and revenue concentration, given that no revenue breakdown is provided?
What is the status and potential financial exposure of the securities class action referenced in recent news?
What are the EPS, P/E, and EV/EBITDA figures, which would allow valuation to be measured against earnings?
What is the company's debt level, since the debt field is reported as N/A for all periods?
What institutional and insider ownership exists, given that the holders section contains no data?

ARDX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Ardelyx Inc. (ARDX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ARDX Debate Forum (3) ↓

🟡 MARKET WIRE Seeking Alpha • 7h ago

Ardelyx: Revisiting The Thesis 2 Years On, I'm Surprised At Lack Of Progress (NASDAQ:ARDX)

Seeking Alpha report covering Ardelyx Inc. (ARDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 10h ago

Ardelyx (NasdaqGM:ARDX) Stock Forecast & Analyst Predictions

Simply Wall St report covering Ardelyx Inc. (ARDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Business Wire • 13h ago

Robbins LLP Urges ARDX Stockholders Who Lost Money Investing in Ardelyx, Inc. to Contact the Firm for Information About Leading the Class Action

Business Wire report covering Ardelyx Inc. (ARDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 16h ago

ARDX Investor Alert: Ardelyx, Inc. Securities Class Action Notice – Contact Levi & Korsinsky

GlobeNewswire report covering Ardelyx Inc. (ARDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 19h ago

Ardelyx Heads These 3 Top Healthcare Stocks To Watch

Simply Wall St report covering Ardelyx Inc. (ARDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH PR Newswire • 22h ago

Ardelyx Deadline: ARDX Investors with Losses in Excess of $100K Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

PR Newswire report covering Ardelyx Inc. (ARDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

Ardelyx (ARDX) Extends Bull Run with Another +2.51% Climb 2026-10-16 - Earnings Miss Risk

https://www.siam.in/ report covering Ardelyx Inc. (ARDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

Ardelyx, Inc. (NASDAQ:ARDX) SHAREHOLDER ALERT:

GlobeNewswire report covering Ardelyx Inc. (ARDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ARDX Bull vs. Bear Conversation Board — What's Your Call at $3.03?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ARDX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.73 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ARDX (E • RQD 24/100) a Buy at $3.10?

Welcome to the ARDX (Ardelyx Inc.) Roar Pit. Current RQD Composite is 24/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.54 (-18.1%)

Spot @ $3.10

Pump the brakes on ARDX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ARDX, but look at what you are paying: current EV/EBITDA multiples with 90.3% gross margins. Unless Ardelyx Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.60 (+16.1%)

Spot @ $3.10

ARDX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ARDX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.10 (52-wk range $2.95 - $8.40), any beat on forward guidance forces shorts and underweight funds to chase.